Role of Cholinergic Signaling in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 139 of the 141 references it cites were found in a registry or an index.
Abstract
Acetylcholine, a neurotransmitter secreted by cholinergic neurons, is involved in signal transduction related to memory and learning ability. Alzheimer’s disease (AD), a progressive and commonly diagnosed neurodegenerative disease, is characterized by memory and cognitive decline and behavioral disorders. The pathogenesis of AD is complex and remains unclear, being affected by various factors. The cholinergic hypothesis is the earliest theory about the pathogenesis of AD. Cholinergic atrophy and cognitive decline are accelerated in age-related neurodegenerative diseases such as AD. In addition, abnormal central cholinergic changes can also induce abnormal phosphorylation of ttau protein, nerve cell inflammation, cell apoptosis, and other pathological phenomena, but the exact mechanism of action is still unclear. Due to the complex and unclear pathogenesis, effective methods to prevent and treat AD are unavailable, and research to explore novel therapeutic drugs is various and active in the world. This review summaries the role of cholinergic signaling and the correlation between the cholinergic signaling pathway with other risk factors in AD and provides the latest research about the efficient therapeutic drugs and treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second-generation AChEIs, including donepezil (4), rivastigmine (5), galantamine (6), are more selective. They exhibited fewer side effects or improved pharmacokinetic profiles, establishing them as first-line drugs for AD.98,400”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is a progressive neurodegenerative disorder and the leading cause of dementia among older adults, characterized by a gradual decline in cognitive function, memory loss, and behavioral changes, ultimately leading to complete dependence on caregivers [7].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these, neurons of the nucleus basalis of Meynert (NBM) are particularly vulnerable, and their degeneration leads to profound reductions in choline acetyltransferase (ChAT) activity within projection areas such as the cerebral cortex and hippocampus, regions essential for learning, memory, and attention [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This hypothesis suggests that a reduction in the synthesis and release of ACh impairs its physiological functions, which are critical for learning, memory, and other cognitive processes.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“The cholinergic hypothesis, one of the earliest and most influential theories of AD, proposed that the characteristic cognitive deficits of the disorder arise primarily from degeneration of cholinergic neurons in the basal forebrain [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hafez, H. S., Ghareeb, D. A., Saleh, S. R., Abady, M. M., Demellawy, M. E., Hussien, H. M., & Abdel-Monem, N. M. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4690-x · Cited by 85
RetractedSemwal, B. C., & Garabadu, D. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08615-1 · Cited by 9 · cited 2×
“Aβ can induce mitochondrial toxicity in the brain, resulting in cognitive dysfunction [5].”
BackgroundRetractedNEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311 · cited 1×
“According to clinical data in recent years, the brains of patients with AD show severe neurodegeneration and reduction of cholinergic neurons and a severe deficiency of Ach; acetylcholine transferase activity is significantly decreased, which further illustrates the damage to the cholinergic system in patients with AD…”
BackgroundEfficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Román, G. C., Jackson, R. E., Gadhia, R., Román, A. N., & Reis, J. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.08.005 · Cited by 421
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312 · cited 1×
“AD is a major cause of dementia which is a common disease among the elderly, starting with an irreversible decline in episodic memory and then a more general decline in overall cognitive ability [2,3].”
BackgroundLiu, Y., Zhang, Y., Zheng, X., Fang, T., Yang, X., Luo, X., Guo, A., Newell, K. A., Huang, X.-F., & Yu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1141-5 · Cited by 285 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
BackgroundLuo, H., Xiang, Y., Qu, X., Liu, H., Liu, C., Li, G., Han, L., & Qin, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00395 · Cited by 264 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
Background
Research works printed but not linked: 1
- Yu, 2019, Protective roles of isoastilbin against Alzheimer’s disease via Nrf2mediated antioxidation and antiapoptosis, Int. J. Mol. Med., 43, 1406
Cited by
Items 601–700 of 1,000
Rotu, R. A., Oyovwi, M. O., Rotu, R. A., Ben‐Azu, B., & Osirim, E. (2026) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-026-00603-3 · Cited by 2
Merzouki, M., Khibech, O., Fraj, E., Elmsellem, H., Chetouani, A., Bouammali, B., & Challioui, A. (2026) · Journal Of Biochemical Technology · doi:10.51847/pthvl9lmg0 · Cited by 2
Ušacka, A., Šneidere, K., Freibergs, Z., & Stepens, A. (2026) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2026.113423 · Cited by 2
小山, 幸., Pham, L., Murakawa, Y., Ogawa, Y., 寺内加奈子, & Davis, K. (2026) · Plants · doi:10.3390/plants15111619 · Cited by 2
Baskar, G., & Kandasamy, M. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.012 · Cited by 2
Liu, C., Zhu, Z., Lin, H., Bush, W. S., Jenq, R. R., Cominelli, F., Pillai, J. A., Haines, J. L., Zhu, X., Xu, R., et al. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1735332 · Cited by 2
Singh, J., Sharma, S., Singh, R., & Singh, P. (2026) · Neuroscience Research and Clinical Practice · doi:10.64229/cztyf245 · Cited by 2
“The degeneration of the basal forebrain cholinergic neurons causes a significant drop in acetylcholine, which disrupts memory, attention and learning mechanisms [40].”
Guo, H., Yang, Z., & Cheng, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1837643 · Cited by 2
“Loss of cholinergic cells in the basal forebrain is a feature of the disease (87).”
Khalifa, M. M., Ibrahim, H. A. M., Gad, M. E., Hassan, I. A. I., Elshanawany, S. A., Mogy, S. A. E., & Fatah, A. I. L. A. E. (2026) · Biological Trace Element Research · doi:10.1007/s12011-026-05199-y · Cited by 2
Sulfonamides: a decade of development in synthetic methods and biological activity studies
Zhang, S., Qin, R. Z., Ajisafe, M. P., & Qin, H. (2026) · Organic & Biomolecular Chemistry · doi:10.1039/d6ob00639f · Cited by 2
Hippocampal prediction errors and claustral control at the perception–memory crossroads
Medina, C., Fernández, R. S., Krawczcyk, M. C., & Boccia, M. M. (2026) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2025.0253 · Cited by 3
Phytocannabinoids: a new frontier in Alzheimer’s disease management
Rao, J. S. (2024) · Academia Biology · doi:10.20935/acadbiol7344 · Cited by 2
Borkowska, P., Kowalczyk, M., Zielińska, A., Poskrobko, K., Rother, M. B., Paul-Samojedny, M., & Kowalski, J. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107053 · Cited by 2
Mahadik, N., Barron, G. A., Lin, P. K. T., & Thompson, C. J. (2025) · Materials Advances · doi:10.1039/d5ma00174a · Cited by 2
Sarkar, S., & Das, S. (2023) · Journal of Essential Oil Bearing Plants · doi:10.1080/0972060x.2023.2286273 · Cited by 2
“The requirement of AD patients to overstimulate the receptors can be achieved via inhibition of AChE using inhibitors (AChEI) 14 .”
BackgroundRecent Advances on Early Diagnosis and Immunotherapy Drug for Alzheimer's Disease
Cui, X., & Lin, H. L. (2024) · MEDS Basic Medicine · doi:10.23977/medbm.2024.020117 · Cited by 2
“Meanwhile, A β is thought to affect cholinergic neurotransmission and lead to reduced choline uptake and acetylcholine release [5].”
BackgroundTargeted Nano-based Drug Delivery in Alzheimer's Disease and Dementia
Mal, P., Rath, S. K., & Halder, T. (2024) · Smart nanomaterials technology · doi:10.1007/978-981-97-0308-1_12 · Cited by 2
Ceyhan, S. M., Bingul, M., Şahin, H., Boğa, M., Sağlam, M. F., Kandemir, H., & Sengul, İ. F. (2024) · Monatshefte für Chemie - Chemical Monthly · doi:10.1007/s00706-024-03230-3 · Cited by 2
Carotenoids in Alzheimer’s Disease and Dementia
Mirzaei, F., Bhatnagar, K., Karingapara, A. S., Kumar, A. S., & Agbaria, L. (2024) · Nutritional neurosciences · doi:10.1007/978-981-97-4117-5_10 · Cited by 2
Takomthong, P., Waiwut, P., Ballatore, C., Choowongkomon, K., Arsito, P. N., Chulikhit, Y., & Boonyarat, C. (2024) · Biomedical Sciences and Clinical Medicine · doi:10.12982/bscm.2024.21 · Cited by 2
Electrochemical Enzyme‐Free Dopamine Sensor Based on Prussian Blue Analogues Oxides and MWCNTs
Xu, W., Chen, Y., & Liu, Y. (2024) · ChemistrySelect · doi:10.1002/slct.202403603 · Cited by 2
Alzheimer’s Disease from Modeling to Mechanism Research
Sun, X., & Zhang, W. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69188-1_7 · Cited by 2
Satish, N., Bukapindi, M., Shreyas, K., Akhil, G., & Malagi, V. P. (2024) · Lecture notes in networks and systems · doi:10.1007/978-981-97-6992-6_20 · Cited by 2
Hadipour, E., Khodadadi, M., Emami, S. A., Rahamouz-Haghighi, S., Ramazani, E., & Tayarani‐Najaran, Z. (2024) · Toxicology Research · doi:10.1093/toxres/tfae217 · Cited by 2
Ghorbani, F., Osatd-Rahimi, N., Mansouritorghabeh, F., Ebrahimzadeh‐Bideskan, A., Saburi, E., Rajabian, A., & Hosseini, M. (2025) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_187_23 · Cited by 2
“Increased AchE activity causes the breakdown of acetylcholine, leading to cholinergic dysfunction followed by cognitive deficits (45).”
Khan, K. A., Esa, M., Kamal, Z., Ullah, B., Perry, G. L., Kamal, S., Ahmad, S., Hussain, H., Ullah, A., & Shafique, M. S. (2025) · Current Neuropharmacology · doi:10.2174/011570159x361867250313073624 · Cited by 2
“This loss impairs synaptic transmission and plasticity and results in cognitive decline and dementia [24].”
Disease-modifying effect of donepezil on APP/PS1 mice at different stages of Alzheimer’s disease
Zueva, I. V., Belyaev, G. P., & Petrov, K. A. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05310-2 · Cited by 2
“As the disease progresses, this correlation becomes increasingly evident, reflecting the progressive loss of cholinergic neurons [39, 40].”
Amin, S., Qusti, S. Y., Al‐Otaibi, W. A., AlMotwaa, S. M., Albogamy, N. T. S., Al‐Seeni, M. N., Alshammari, E. M., Babaker, M. A., & Saeed, A. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04443-6 · Cited by 2
Bahloul, A., Messaâd, M., Smaoui, S., Dammak, T., Khemakhem, B., & Abdelhedi, M. (2025) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2025.115002 · Cited by 2
Pandey, D., & Gokhale, K. M. (2025) · Metallurgical and Materials Engineering · doi:10.63278/mme.vi.1832 · Cited by 2
Anadozie, S. O., Adetimehin, W. T., & Adewale, O. B. (2025) · Tropical Journal of Natural Product Research · doi:10.26538/tjnpr/v9i11.54 · Cited by 2
Failure of current Alzheimer’s disease hypotheses
Wood, P. L. (2023) · Aging · doi:10.18632/aging.204880 · Cited by 2
Olugbogi, E. A., Omirin, E. S., Omoseeye, S. D., Adebisi, A. D., Owolabi, B. T., Aderiye, M. A., Ajayi, O. M., Onekhena, V. O., Olatunji, D. A., Adetunji, R. A., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3875869/v1 · Cited by 2
Biswas, K., Moore, C. M., Rogers, H., Wani, K. A., Mushtaq, A., Pukkila-Worley, R., Higgins, D. P., Walker, A. K., Mullen, G. P., Rand, J. B., et al. (2026) · eLife · doi:10.7554/elife.107726 · Cited by 2
Ultrafast spin coherence reveals ion-pairing–mediated molecular dynamics in solutionPreprint
Rothbaum, J. O., Whiteside, J. C., Sutcliffe, E., Aalto, J. P., Kazmierczak, N. P., & Hadt, R. G. (2026) · ChemRxiv · doi:10.26434/chemrxiv.15000874/v1 · Cited by 2
Primary Cilia and Cardiovascular Risk Factors in Alzheimer's Disease
Sunderman, C. L., Forero, K. V., Alorjani, Q., Buqaileh, R., Gallagher, G. M., Ventresca, S. M., Messer, W. S., & AbouAlaiwi, W. A. (2025) · Brain Sciences · doi:10.3390/brainsci15091004 · Cited by 1
“AChEIs, including the FDA-approved donepezil, galantamine, and rivastigmine, can relieve cognitive dysfunction and reduce cognitive decline in mild to moderate AD patients [60,61].”
Espinosa, M. C. (2024) · Estudios y Perspectivas Revista Científica y Académica · doi:10.61384/r.c.a..v4i2.247 · Cited by 1
Traditional Herbal Medicine for Dementia Therapy
Sosa, A. E., & Hassan, Z. (2024) · Nutritional neurosciences · doi:10.1007/978-981-97-4117-5_12 · Cited by 1
Molecular Modeling Insights on the Pharmaceuticals and Hypotheses of Alzheimer’s Disease
de Castro, A. A., Silva, H. F., Garcia, M. V. F. P., Homem‐de‐Mello, P., & Ramalho, T. C. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673318143240823064403 · Cited by 1
Pal, M., Maurya, A., Shukla, R., Siddiqui, Z., Pathak, S. K., Srivastava, R., Shukla, V. K., Prasad, O., & Sinha, L. (2024) · Molecular Simulation · doi:10.1080/08927022.2024.2397463 · Cited by 1
“A notable area of interest in Alzheimer ’ s research centres around AChE inhibitors, which have gained signi fi cant attention as a potential therapeutic approach for managing the symptoms of this disease, primarily based on the cholinergic hypothesis [5,12,13].”
Guan, J., Noviasky, J. A., & Watanabe, J. H. (2024) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2024.449 · Cited by 1
Wild Mushrooms as a Source of Cholinesterase and Glutathione S-Transferase Inhibitors
Trobec, T., Kurešepi, E., Popošek, L. L., Šparl, L., Frangež, R., Skočaj, M., & Sepčić, K. (2025) · International journal of medicinal mushrooms · doi:10.1615/intjmedmushrooms.2025058221 · Cited by 1
Khan, M. S., Islam, T., Farooq, M. U., al‐Arifa, N., Jalil, S., Khan, I. A., Hameed, A., Asari, A., Rehman, A. U., Iqbal, J., et al. (2025) · ChemistrySelect · doi:10.1002/slct.202405063 · Cited by 1
Erdogan, O., İyigün, C., & Son, Y. A. (2025) · BioData Mining · doi:10.1186/s13040-025-00436-x · Cited by 1
“Interestingly, the relationship between nicotinic activity in dopaminergic neurons and Alzheimer’s disease (AD) is complex, and the specific effects of nicotine on dopaminergic neurons in the context of cognitive impairment, memory loss, and development of AD are still being investigated [33].”
Khatun, M. M., Oni, M., Shadin, M., & Bodiuzzaman, B. S. M. (2025) · Journal of Medicinal Chemistry and Therapeutics · doi:10.71193/jmct.20250001 · Cited by 1
Thawkar, B. S., & Kaur, G. (2025) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.24.03153-5 · Cited by 1
The potential therapeutic effect of donepezil on a ketamine rat model of psychosis
Mehdar, K. M. (2025) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/oddqdge3fy · Cited by 1
“It uniquely inhibits both the core and peripheral catalytic sites of acetylcholinesterase, increasing acetylcholine levels by preventing its breakdown [22].”
Rullmann, M., Meyer, P., Schildan, A., Hoffmann, K., Sabri, O., & Tiepolt, S. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07383-z · Cited by 1
Neurodegenerative Diseases and Succinate Dehydrogenase: A Therapeutics Avenue for Treatment
Viswalingam, V., & Kumar, D. (2025) · Springer eBooks · doi:10.1007/978-981-96-6831-1_9 · Cited by 1
Azman, P. N. N. N., Amran, M., Ali, A. H., Hanafi, W. N. W., & Hassan, W. R. M. (2025) · Science Letters · doi:10.24191/scl.v19i2.6906 · Cited by 1
Gyebi, G. A., Rotimi, D. E., Oduba, M., Nnonyelu, I., Iyobhebhe, M. E., Salawu, M. A., Ojo, A. B., Taiwo, O. A., Olanrewaju, A. A., Oyebamiji, A. K., et al. (2025) · Food Safety and Health · doi:10.1002/fsh3.70036 · Cited by 1
“By impeding the activity of these enzymes, cholinergic transmission in the brain can be increased (Moreira et al. 2022; Chen et al. 2022).”
de Oliveira, T. B., Galeriani, A. C. B., de Souza, J. R. R., Kawano, D. F., Trevisan, M. T. S., & Almeida, W. P. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf055 · Cited by 1
Sandrine, M. N. Y., Owona, P. E., Ella, F. A., Bilanda, D. C., Julie, A. O. J., Cynthia, B. Y. P., Michel, B. G., Dzeufiet, P. D. D., Binsaleh, A. Y., Alwethaynani, M. S., et al. (2025) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416525501248 · Cited by 1
Laxmi, I. P. L., & Tamizhselvi, R. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04551-3 · Cited by 1
Alzheimer’S disease and It’s management: A review
Manke, M. B., Kalshetti, M. P., Giram, P. S., & Bhusnure, O. G. (2025) · Current Trends in Pharmacy and Pharmaceutical Chemistry · doi:10.18231/j.ctppc.v.7.i.3.1 · Cited by 1
Munc 18–1 is a multifaceted therapeutic target for dementia
Singh, K. S., Rani, P., Arora, A., Verma, R., Gupta, A., & Singh, L. R. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102899 · Cited by 1
de Souza, F. N., de Oliveira, N. K. S., de Lima, H. B., Silva, A. G., Cruz, R. A. S., de Oliveira, F. R., Federico, L. B., & Hage-Melim, L. I. D. S. (2025) · Applied Sciences · doi:10.3390/app151910340 · Cited by 1
Ahmad, S., Siddiqua, A., Abbas, E., Wasim, M., Zia, S. R., Khan, A., Siddiqi, H. S., Arain, F. M., Tabassum, S., Khaliq, S., et al. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501374 · Cited by 1
Kwon, H., Kwon, M. H., Jeong, M., Kim, Y., Yoon, H.-G., Ju, Y., Hyun, K., & Choi, G. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100817 · Cited by 1
“Acetylcholine (ACh) is an important neurotransmitter involved in memory and learning, among other functions [3,4].”
Kordinová, H., Mik, V., Hemelíková, N., Gonzalez, G. A., Štěpánková, Š., Górová, V., Bazgier, V., & Kvasnica, M. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118217 · Cited by 1
Kumari, B. L., Kumar, R. K., Sakharam, K. A., Damare, R., Singh, S. B., & Kumar, G. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70115 · Cited by 1
“Furthermore, a decline in the expression of Ach receptors also contributed significantly to neuron degeneration [65, 66].”
Research progress of intestinal microbiota on cognitive dysfunction after spinal cord injury
Tian, C., Chang, X., Wu, J., Xiao, L., Du, J., Hu, Q., & Yang, Y. (2025) · iScience · doi:10.1016/j.isci.2025.113554 · Cited by 1
“51 Studies have shown that damage to cholinergic receptors in the hippocampal CA3 region interrupts neural signaling and causes cognitive impairment.”
Anticholinergics, executive function, and cognitive/behavioral changes in Down syndrome
Lee, N., McQuaid, G. A., Jiddou, H., McNulty, J., Grosman, H. E., Tucker, K. T., O’Brien, M., & Wallace, G. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70649 · Cited by 1
Öztürk, O., Oyardı, Ö., Sağkan, R. I., & Dündar, Y. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118445 · Cited by 1
Uddin, M. J., Lela, L., Carlucci, V., Milella, L., & Zidorn, C. (2025) · Fitoterapia · doi:10.1016/j.fitote.2025.106940 · Cited by 1
From the hive to the brain: synergistic potential of honeybee products with alzheimer’s drugs
El-Seedi, H. R., Salama, S. M., Shetaia, A. A., Elashal, M. H., El‐Wahed, A. A. A., Karav, S., Saeed, A., Alzahrani, M. A., Zou, X., Hriţcu, L., et al. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01727-2 · Cited by 1
“The cholinergic hypothesis was suggested in the 1970 s, where the connection between the neocortical and presynaptic cholinergic deficits and the choline acetyltransferase enzyme was assumed to play the main role in decline of the cognitive function (Chen et al. 2022).”
Neuroprotective effects of Urtica dioica Linn. on diabetic animal models: A systematic review
Bayat, R., Nazari, Z., Alami, K., & Mousavi, S. Y. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120815 · Cited by 1
Hazra, A., Hoda, M., Jethwa, M., Saha, A., & Das, S. (2025) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-025-05471-2 · Cited by 1
Palanivelu, A., Veeraraghavan, B., Mohan, D., Ashok, C., Jeyabalan, S., Wong, L. S., Sekar, M., Subramaniyan, V., Dhanasekaran, S., & Thamaraikani, T. (2025) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2025.100719 · Cited by 1
Amin, O. M., Khalifa, M. K. A., El-Fattah, M. A. A., Allam, A., Aboutaleb, A. S., & Al‐Najjar, A. H. (2025) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2025.2592102 · Cited by 1
Mindful Eating: Ayurvedic Insights into Diet and Alzheimer’s Disease Management
Dahiya, J., Mangal, A. K., Ghosh, A., Roy, S., & Babu, G. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-2736-6_8 · Cited by 1
Phosphonates and the brain, from diagnostics to medicines for neurological disorders
Braga, S. S., Santos, N. E., Almeida-Santos, M., Figueira, F., & Paz, F. A. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33374-3.00016-5 · Cited by 1
Ahmed, A., Khan, H. R., Shen, Y., Xu, S., Zhao, Y., Lv, J., Zhu, X., Fu, X., & Li, P. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251404020 · Cited by 1
“103,104 106 And thereby increase cholinergic transmission in the brain.”
Muthuramalingam, K., & Lee, H. J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251407702 · Cited by 1
Sudhakar, S., & Deepam, L. S. A. (2025) · Discover Chemistry. · doi:10.1007/s44371-025-00426-2 · Cited by 1
“The decrease in acetylcholine (ACh) levels in the brain is the ultimate reason for neurodegenerative disorders [109].”
Emergence of a Potent AChE Inhibitor with Antioxidant and Neuroprotection Abilities
Osama, A., Ji, M., Fang, J., Zhao, H., & Zhang, B. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00524 · Cited by 1
Chabane, S., Boudjelal, A., Demirtaş, İ., Bouchahdane, S., Tail, G., Yenigün, S., Özen, T., Yıldız, İ., & Amrane, A. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.121135 · Cited by 1
Sadaf, D. S., Dawood, S., Emad, S., Yousuf, S., Qadeer, S., Sarfaraz, Y., Sheikh, S., & Perveen, T. (2026) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps.2026.39.2.reg.14550.1 · Cited by 1
Mandloi, U., Giri, N., Kumar, S., & Modi, G. P. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00713e · Cited by 1
Yadav, R., Mani, R. J., SHARMA, A. K., KUMAR, A., & Katare, D. P. (2026) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2026v18i1.56212 · Cited by 1
Dewangan, A. K., Nandy, S. K., Das, A. K. K., Sharma, A., & Sharma, L. (2026) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273418918251112112429 · Cited by 1
Structure-guided design and synthesis of selective butyrylcholinesterase inhibitors
Law, C. S. W., Ha, Z. Y., Brazzolotto, X., & Yeong, K. Y. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.145611 · Cited by 1
Hasan, A. H., Rana, S., Kumer, A., Hossain, N., Sezin, S. N., Islam, M. T., Molla, N. U., Hosen, M. N., Maha, N. M., Mahi, M. M., et al. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100234 · Cited by 1
Kim, I. Y., Kim, J., Lee, H. L., Lee, H. S., Kim, J. H., Choi, H. J., & Heo, H. J. (2026) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2510.10048 · Cited by 1
Mani, V., & Almatrafi, M. A. (2026) · Life · doi:10.3390/life16020315 · Cited by 1
Köprülü, C., Faydalı, N., Muhammed, M. T., Dilek, E., Küçükoğlu, K., & Şirinzade, H. (2026) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2026.102484 · Cited by 1
Gonzalez, M., West, R. M., Tsang, A., Ocampo, O., Hudson, P. K., & Pecic, S. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103159 · Cited by 1
Jadhav, V. P., & Mohanty, P. K. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04711-z · Cited by 1
Sonu, Alomar, T. S., Parveen, B. R., Altalhi, R., Sayed, A. A., AlMasoud, N., Abdel‐Daim, M. M., Yadav, P., Kumar, A., & Kapoor, K. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109687 · Cited by 1
Chauhan, P., Wadhwa, K., & Singh, G. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121509 · Cited by 1
Khan, P. A. (2026) · Research Journal of Biotechnology · doi:10.25303/214rjbt2800284 · Cited by 1
Neurobiological links between Alzheimer’s disease and reward system dysfunction
Harutyunyan, H. S., Minasyan, R., Kalueff, A. V., & Yenkoyan, K. B. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.03.028 · Cited by 1
Ojo, O. A., Gyebi, G. A., Iyobhebhe, M. E., Dada, S., Daramola, T. O., Ojo, A. B., Oyebamiji, A. K., Oyinloye, B. E., & Ajiboye, B. O. (2026) · Scientific Reports · doi:10.1038/s41598-026-45482-5 · Cited by 1
“In AD pathology, abnormal cholinergic functioning is characterized by elevated AChE activity 56 .”
Guo, C., Qu, B., Li, H., Li, X., Liu, B., Wang, X., Xue, Y., Ning, C., Wang, S., Wu, J., et al. (2026) · Foods · doi:10.3390/foods15071126 · Cited by 1
“Acetylcholinesterase (AChE) is the key hydrolase that catalyses the degradation of synaptic ACh; its abnormal overactivation accelerates ACh depletion, disrupting neural signal transmission and exacerbating AD pathological progression [2].”
Tiwari, S., Yadav, S. K., Kumari, M., Dhakal, T., & Puranik, N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073206 · Cited by 1
A specific pilose antler peptide LVLVEAELRE ameliorates cognitive deficits in SAMP8 mice via Celsr2
Sun, Z., Peng, Q., Qiu, C., Jia, X., Wang, H., Wu, S., & Tao, W. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121649 · Cited by 1
Singh, A., Sahu, S. K., & Sah, A. K. (2026) · BioMed Research International · doi:10.1155/bmri/5968529 · Cited by 1
“By inhibiting this enzyme, these medications help maintain larger amounts of ACh at neuronal synapses, somewhat compensating for cholinergic neuron loss reported in Alzheimer's patients [44].”
Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer’s disease therapy
Ouro, A., Ben-Dor, G. A., Debasa‐Mouce, M., Gulkarov, S., Leon, J. D., Castro‐Mosquera, M., Sobrino, T., Bougea, A. M., & Reiss, A. B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1766762 · Cited by 1
“Cholinergic inhibitors are pertinent small molecules for discussion since their use is widespread and common (Chen et al., 2022).”
Enteric Nervous System Damage by Food Contaminants: A Pathway to Neurodegeneration?
Ramos, H., Araújo, A. M., Ferreira, I. M. P. L. V. O., & Faria, M. Â. (2026) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.70448 · Cited by 1
Kherachi, R., Daoud, I., Melkem, N., Chelihi, A., Al‐Shuhaib, M. B. S., Hamouda, S. H. H., Meawad, S. B., El‐Arabey, A. A., & ABDALLA, M. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00605-8 · Cited by 1
Metadata
- Authors
- Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F.
- Affiliations
- Nanchang University (CN)
- Experimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China
- Corresponding author
- Yang, Shu-Long
- Hong, Fen-Fang
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-03-10
- Volume
- 27
- Issue
- 6
- Pages
- 1816
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8949236
- OpenAlex
- W4220945110
- Cited by
- 922
- References
- 141
- Citations by year
- 2026: 256 · 2025: 347 · 2024: 202 · 2023: 87 · 2022: 29
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82060661, 81660751, 81660151)
- Jiangxi Provincial Natural Science Foundation of China (20212BAB206092)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic neurotransmission, acetylcholine, cholinergic hypothesis, cognitive decline, tau phosphorylation, neuroinflammation, apoptosis, Alzheimer's disease pathogenesis, Alzheimer's disease therapeutics
- MeSH terms
- Acetylcholine, Alzheimer Disease, Humans, Signal Transduction, Cholinergic Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.